Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt No Debt
GALT's Cash to Debt is ranked higher than
99% of the 759 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.46 vs. GALT: No Debt )
Ranked among companies with meaningful Cash to Debt only.
GALT' s Cash to Debt Range Over the Past 10 Years
Min: 0.41  Med: 10000.00 Max: No Debt
Current: No Debt
Interest Coverage No Debt
GALT's Interest Coverage is ranked higher than
98% of the 461 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 21.31 vs. GALT: No Debt )
Ranked among companies with meaningful Interest Coverage only.
GALT' s Interest Coverage Range Over the Past 10 Years
Min: 9999.99  Med: 10000.00 Max: 9999.99
Current: No Debt
F-Score: 2
Z-Score: -8.66
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
ROE (%) -138.80
GALT's ROE (%) is ranked lower than
96% of the 739 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.16 vs. GALT: -138.80 )
Ranked among companies with meaningful ROE (%) only.
GALT' s ROE (%) Range Over the Past 10 Years
Min: -1658.88  Med: -164.46 Max: -107.68
Current: -138.8
-1658.88
-107.68
ROA (%) -86.37
GALT's ROA (%) is ranked lower than
96% of the 763 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.71 vs. GALT: -86.37 )
Ranked among companies with meaningful ROA (%) only.
GALT' s ROA (%) Range Over the Past 10 Years
Min: -1309.12  Med: -143.39 Max: -56.38
Current: -86.37
-1309.12
-56.38
ROC (Joel Greenblatt) (%) -11026500.00
GALT's ROC (Joel Greenblatt) (%) is ranked lower than
100% of the 757 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 14.16 vs. GALT: -11026500.00 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
GALT' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -4015800  Med: -89452.98 Max: -6978.38
Current: -11026500
-4015800
-6978.38
EBITDA Growth (3Y)(%) 9.20
GALT's EBITDA Growth (3Y)(%) is ranked higher than
55% of the 550 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.40 vs. GALT: 9.20 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
GALT' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -6.00 Max: 11.3
Current: 9.2
0
11.3
EPS Growth (3Y)(%) 6.90
GALT's EPS Growth (3Y)(%) is ranked higher than
51% of the 507 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.10 vs. GALT: 6.90 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
GALT' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -33.6  Med: -3.20 Max: 36.2
Current: 6.9
-33.6
36.2
» GALT's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-08-10)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

GALT Guru Trades in

GALT Guru Trades in

GALT Guru Trades in

Q2 2014

GALT Guru Trades in Q2 2014

George Soros Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with GALT

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare:NAS:STDY, OTCPK:ACBFF, NAS:ADMP, NAS:MEIP, NAS:FCSC, OTCPK:BKIT, NAS:OREX, OTCPK:AOLS, NAS:PTX, NAS:IMMY, NAS:SCYX, OTCPK:NRIFF, OTCPK:RLMD, NAS:ACUR, NAS:CPRX, OTCPK:GLDFF, AMEX:PVCT, NAS:APRI, OTCPK:ALXA, NAS:ZYNE » details
Traded in other countries:PHPN.Germany,
Galectin Therapeutics Inc is a clinical stage biopharmaceutical company. The Company is engaged in drug research and development to create new therapies for fibrotic disease and cancer.

Galectin Therapeutics Inc was incorporated in Nevada on January 26, 2001 as DTR-Med Pharma Corp. On May 10, 2001, DTR changed its name to Pro- Pharmaceuticals, Inc. On May 26, 2011, Pro-Pharmaceuticals, Inc. changed its name to Galectin Therapeutics Inc. Galectin Therapeutics is a development-stage company, which is engaged in drug development to create new therapies for cancer and fibrotic disease. The Company's drug candidates are based on its method of targeting galectin proteins, which are key mediators of biologic and pathologic function. The Company uses naturally occurring plant materials to create complex carbohydrates with specific molecular weights and pharmaceutical properties. The Company focuses on diseases with serious, life-threatening consequences to patients and those where current treatment options are limited. The Company has two compounds in development, one intended to be used in cancer therapy and the other intended to be used in the treatment of liver fibrosis and fatty liver disease. These two compounds are produced from completely different natural starting materials, both possessing the property which lends itself to binding to and inhibiting galectin proteins. GM-CT-01, its product candidate for cancer therapy, is a proprietary linear polysaccharide polymer comprised of mannose and galactose that has a precisely defined chemical structure and is derived from a plant source. GR-MD-02, its other product for treatment of liver fibrosis and fatty liver disease with inflammation and fibrosis, is a proprietary complex polysaccharide polymer possessing both linear and globular structures, which also is derived from a plant source. Its competitors include multinational pharmaceutical and chemical companies, specialized biotechnology firms and universities and other research institutions. The research, development, testing, manufacture, labeling, promotion, advertising, distribution, and marketing, among other things, of its products are extensively regulated by governmental authorities in the United States and other countries.

Ratios

vs
industry
vs
history
P/B 3.63
GALT's P/B is ranked lower than
59% of the 769 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.98 vs. GALT: 3.63 )
Ranked among companies with meaningful P/B only.
GALT' s P/B Range Over the Past 10 Years
Min: 0  Med: 0.00 Max: 457.5
Current: 3.63
0
457.5
EV-to-EBIT -0.98
GALT's EV-to-EBIT is ranked lower than
99.99% of the 544 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 21.83 vs. GALT: -0.98 )
Ranked among companies with meaningful EV-to-EBIT only.
GALT' s EV-to-EBIT Range Over the Past 10 Years
Min: -1.25  Med: 0.00 Max: 0
Current: -0.98
-1.25
0
EV-to-EBITDA -0.98
GALT's EV-to-EBITDA is ranked lower than
99.99% of the 576 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 17.31 vs. GALT: -0.98 )
Ranked among companies with meaningful EV-to-EBITDA only.
GALT' s EV-to-EBITDA Range Over the Past 10 Years
Min: -1.25  Med: 0.00 Max: 0
Current: -0.98
-1.25
0
Current Ratio 7.01
GALT's Current Ratio is ranked higher than
85% of the 675 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.40 vs. GALT: 7.01 )
Ranked among companies with meaningful Current Ratio only.
GALT' s Current Ratio Range Over the Past 10 Years
Min: 0.2  Med: 4.01 Max: 23.21
Current: 7.01
0.2
23.21
Quick Ratio 7.01
GALT's Quick Ratio is ranked higher than
86% of the 675 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.78 vs. GALT: 7.01 )
Ranked among companies with meaningful Quick Ratio only.
GALT' s Quick Ratio Range Over the Past 10 Years
Min: 0.2  Med: 4.01 Max: 23.21
Current: 7.01
0.2
23.21

Valuation & Return

vs
industry
vs
history
Price/Net Cash 3.57
GALT's Price/Net Cash is ranked higher than
76% of the 245 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 12.66 vs. GALT: 3.57 )
Ranked among companies with meaningful Price/Net Cash only.
GALT' s Price/Net Cash Range Over the Past 10 Years
Min: 2.69  Med: 12.62 Max: 221
Current: 3.57
2.69
221
Price/Net Current Asset Value 3.66
GALT's Price/Net Current Asset Value is ranked higher than
75% of the 491 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.43 vs. GALT: 3.66 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
GALT' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 2.69  Med: 12.84 Max: 732
Current: 3.66
2.69
732
Price/Tangible Book 3.63
GALT's Price/Tangible Book is ranked higher than
51% of the 712 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.77 vs. GALT: 3.63 )
Ranked among companies with meaningful Price/Tangible Book only.
GALT' s Price/Tangible Book Range Over the Past 10 Years
Min: 2.71  Med: 12.58 Max: 430
Current: 3.63
2.71
430
Price/Projected FCF 4.29
GALT's Price/Projected FCF is ranked lower than
62% of the 308 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.65 vs. GALT: 4.29 )
Ranked among companies with meaningful Price/Projected FCF only.
GALT' s Price/Projected FCF Range Over the Past 10 Years
Min: 2.73  Med: 5.00 Max: 115.43
Current: 4.29
2.73
115.43
Earnings Yield (Greenblatt) (%) -102.00
GALT's Earnings Yield (Greenblatt) (%) is ranked lower than
98% of the 780 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.90 vs. GALT: -102.00 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
GALT' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -338.41  Med: 0.00 Max: 0
Current: -102
-338.41
0

More Statistics

EPS (TTM) $ -0.90
Beta1.48
Short Percentage of Float2.39%
52-Week Range $1.08 - 3.33
Shares Outstanding (Mil)28.98

Analyst Estimate


Warning: Invalid argument supplied for foreach() in /home/gurufocu/public_html/modules/stock/estimate.php on line 163
Dec16 Dec17 Dec18
Revenue (Mil $)
EPS ($) -1.00 -0.85 -0.83
EPS w/o NRI ($) -1.00 -0.85 -0.83
EPS Growth Rate
(3Y to 5Y Estimate)
N/A
Dividends Per Share ($)

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)